Research Study

A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Principal Investigator 
Brian Kwon

Overview

Body Locations and Systems 
Spine
ClinicalTrials.gov# 
NCT02669849
Status 
Recruiting
Study Start/End 
Jul 24, 2017 to Jun 1, 2019
Locations 
Vancouver General Hospital
Name/Title 
Alan Aludino/Spine Research Program Manager
Phone 
604-875-4111 Ext: 61689
Purpose of Study 

This is a Phase 2b/3 study.  The purpose of a 2b/3 study is to learn more about the safety and effects of VX-210 in patients with acute traumatic cervical SCI.  VX-210 is an investigational drug; “investigational” means the drug is not approved by Health Canada or the US Food and Drug Administration (FDA) and is still being tested for safety and effectiveness. 

VX-210 will be combined with a commonly used fibrin sealant during your surgery. Fibrin sealants are approved, marketed products used for tissue sealing or to stop bleeding. They are often used during surgery after spinal cord injury.

This multicenter study will evaluate effect of VX-210 on the recovery of muscle strength and sensation following SCI.  This study will also assess the impact of VX-210 on the ability to perform activities of daily living (ADLs) and the need for attendant care following injury. 

Eligibility 

See ClinicalTrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.